The risks and benefits of antibacterial therapy should be considered in prescribing decisions. Pharmacologic and epidemiologic data point to lethal arrhythmias as a potential consequence of QT-interval prolongation with use of azithromycin, other macrolides, and fluoroquinolones. This possibility should give clinicians pause when they’re considering prescribing antibacterial drugs, especially for patients with preexisting cardiovascular risk factors or clinical conditions in which antibacterial drug therapy has limited benefits.
Azimmaxx 500 TABLET
From the Office of Surveillance and Epidemiology, Division of Epidemiology II (A.D.M., J.M.), the Office of Antimicrobial Products, Division of Anti-Infective Products (J.J.A., S.N.), and the Office of Communications, Division of Health Communications (H.S.), Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Out of stock